Oppenheimer & Co. Inc. Sells 1,168 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Oppenheimer & Co. Inc. reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,265 shares of the medical research company's stock after selling 1,168 shares during the period. Oppenheimer & Co. Inc.'s holdings in Thermo Fisher Scientific were worth $18,721,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.4% during the first quarter. Vanguard Group Inc. now owns 33,095,791 shares of the medical research company's stock valued at $19,235,605,000 after purchasing an additional 117,353 shares in the last quarter. Capital World Investors raised its position in Thermo Fisher Scientific by 10.0% during the first quarter. Capital World Investors now owns 13,493,852 shares of the medical research company's stock valued at $7,842,762,000 after purchasing an additional 1,231,059 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Thermo Fisher Scientific by 1.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,054,621 shares of the medical research company's stock valued at $5,843,848,000 after purchasing an additional 156,675 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Thermo Fisher Scientific by 1.5% during the first quarter. Capital Research Global Investors now owns 8,113,137 shares of the medical research company's stock worth $4,715,436,000 after buying an additional 123,523 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Thermo Fisher Scientific by 32.2% during the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock worth $1,372,157,000 after buying an additional 604,895 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.2 %

Shares of Thermo Fisher Scientific stock traded up $1.15 during mid-day trading on Wednesday, hitting $541.90. The stock had a trading volume of 1,199,648 shares, compared to its average volume of 1,461,625. The firm has a 50-day moving average of $591.27 and a two-hundred day moving average of $583.32. Thermo Fisher Scientific Inc. has a 12-month low of $455.22 and a 12-month high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $207.28 billion, a P/E ratio of 33.97, a price-to-earnings-growth ratio of 3.57 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. During the same quarter in the previous year, the business posted $5.69 EPS. The firm's revenue was up .2% on a year-over-year basis. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific's payout ratio is currently 9.78%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 over the last quarter. Corporate insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a report on Thursday, July 25th. Stephens began coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 price objective for the company. Bank of America increased their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a report on Monday, September 16th. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Finally, UBS Group raised shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.